Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

✍ Scribed by Peter C. Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt

• Book ID: 116430798
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 282 KB
• Volume: 47
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2011.06.002